WO2008061968A1 - Dérivés de benzimidazolone utiles dans le traitement de l'hypertension artérielle pulmonaire - Google Patents
Dérivés de benzimidazolone utiles dans le traitement de l'hypertension artérielle pulmonaire Download PDFInfo
- Publication number
- WO2008061968A1 WO2008061968A1 PCT/EP2007/062537 EP2007062537W WO2008061968A1 WO 2008061968 A1 WO2008061968 A1 WO 2008061968A1 EP 2007062537 W EP2007062537 W EP 2007062537W WO 2008061968 A1 WO2008061968 A1 WO 2008061968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- use according
- pah
- formula
- compound
- acid addition
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title claims description 23
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000012458 free base Substances 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000029147 Collagen-vascular disease Diseases 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 208000007232 portal hypertension Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 150000007513 acids Chemical class 0.000 claims 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 abstract description 2
- 150000008641 benzimidazolones Chemical class 0.000 abstract description 2
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 239000003826 tablet Substances 0.000 description 18
- 229920002261 Corn starch Polymers 0.000 description 12
- 239000008120 corn starch Substances 0.000 description 12
- 239000013543 active substance Substances 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- IODUMQSUUADSTG-UHFFFAOYSA-N 5-Hydroxytryptamin Natural products C1=C(O)C=C2C(CN)CNC2=C1 IODUMQSUUADSTG-UHFFFAOYSA-N 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000007941 film coated tablet Substances 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 maleic Chemical class 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 101150075901 htr2 gene Proteins 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the invention relates to the use of benzimidazolone derivatives of formula (I) for preparing a medicament for treating diseases in which the use of therapeutic effective amounts of compounds displaying affinity for the 5-HT 2B -receptor display a therapeutic benefit.
- R 1 , R 2 , R 3 , and R 4 denote hydrogen or hydroxy with the proviso that R 1 , R 2 , R 3 , and R 4 cannot simultaneously represent hydrogen.
- Preferred compounds according to the invention are those of general formula (I) wherein two or three of the four radicals R1 , R2, R3, and R4 denote hydrogen. Also preferred are compounds of general formula (I) wherein one of the radicals R1 , R2, R3, and R4 denotes hydroxy, whilst the other radicals represent hydrogen.
- 5-HT1 A and 5-HT2-receptor show affinity for the 5-HT1 A and 5-HT2-receptor. They may be of value in the treatment of those diseases where an altered functioning of neurosignal transmission is present. Examples of these CNS disorders include depression, schizophrenia, Parkinson, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment (WO 01/21593 A1 ).
- the compounds of formula (I) ⁇ optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof show affinity for the 5-HT 2B -receptor with antagonistic activity.
- the instant invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating diseases in which the use of therapeutic effective amounts of compounds displaying affinity for the 5-HT 2B -receptor display a therapeutic benefit.
- the instant invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating diseases in which the use of therapeutic effective amounts of compounds displaying antagonistic activity to the 5-HT 2B -receptor display a therapeutic benefit.
- Pulmonary arterial hypertension is the clinical term used to describe a condition associated with progressive elevation in pulmonary arterial pressure (by 10-15 mmHg). PAH occurs more commonly secondary to collagen vascular disease, congenital systemic to pulmonary shunt, portal hypertension, human immunodeficiency virus infection, chronic obstructive lung diseases, interstitial fibrosis and high left-sided filling pressures.
- pulmonary vascular tone is regulated by a balance between the effects of vasodilators/antiproliferative agents such as prostacyclin and nitric oxide and vasoconsthctors/co-mitogens such as 5-HT (5-Hydroxytryptamin). Alterations in 5-HT turnover lead to an increased availability of free 5-HT in the vicinity of the pulmonary artery wall. Under normal conditions, the lung vascular bed is not exposed to excessive 5-HT levels, because of its position as a secondary filter located downstream from the liver and because of the ability of platelets to store large amounts of 5-HT.
- vasodilators/antiproliferative agents such as prostacyclin and nitric oxide
- vasoconsthctors/co-mitogens such as 5-HT (5-Hydroxytryptamin). Alterations in 5-HT turnover lead to an increased availability of free 5-HT in the vicinity of the pulmonary artery wall.
- the lung vascular bed is not exposed to excessive 5-HT levels, because of its position as a
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating Pulmonary arterial hypertension (PAH).
- PAH Pulmonary arterial hypertension
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH secondary to collagen vascular disease.
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH congenital systemic to pulmonary shunt.
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH secondary to portal hypertension.
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH secondary to human immunodeficiency virus infection.
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH secondary to chronic obstructive lung diseases.
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH secondary to interstitial fibrosis.
- the invention relates to the use of one or more, preferably one compound of formula (I) ⁇ _, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof for the preparation of a medicament for preventing and/or treating PAH secondary to high left-sided filling pressures.
- Another embodiment of the invention relates to a method for preventing and/or treating of any of the aforementioned conditions, comprising the administration of a therapeutically effective amount of one or more, preferably one compound of formula (I) 1, optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof.
- the present invention relates to any of the above mentioned uses and methods wherein 1_ is selected from the group consisting of
- the compounds of formula (I) l and the compounds (I. a), (l.b), (l.c), (l.d), (l.e), (l.f), (l.g) and (l.h) can be used either as free base or in form of its pharmaceutically acceptable acid addition salts.
- the term ..acceptable acid addition salts includes both organic and inorganic acids such as maleic, citric, tartaric, methanesulphonic, acetic, benzoic, succinic, gluconic, isethionic, glycinic, lactic, malic, mucoic, glutamic, sulphamic and ascorbic acid; inorganic acids include hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acid. Mixtures of the above mentioned acid addition salts may also be used.
- the present invention includes within its scope prodrugs of the compounds ⁇ _.
- prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
- terapéuticaally effective amount shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
- the compounds of formula (I) l and the compounds (I. a), (l.b), (l.c), (l.d), (l.e), (l.f), (l.g) and (l.h), optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof., may be incorporated into the conventional pharmaceutical preparation in solid, liquid or spray form.
- the composition may, for example, be presented in a form suitable for oral, rectal, parenteral administration or for nasal inhalation: preferred forms includes for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray.
- the compounds of formula (I) l and the compounds (I. a), (l.b), (l.c), (l.d), (l.e), (l.f), (l.g) and (l.h), may be incorporated in excipients or carriers conventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, acqueous or non acqueous vehicles, polyvynil pyrrolidone, semisynthetic glicerides of fatty acids, benzalconium chloride, sodium phosphate , EDTA, polysorbate 80.
- excipients or carriers conventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, acqueous or non acqueous vehicles, polyvynil pyrrolidone, semisynthetic glicerides of fatty
- compositions are advantageously formulated in dosage units, each dosage unit being adapted to supply a single dose of the active ingredient.
- the dose range applicable per day is between 0.1 to 400, preferably between 1.0 to 300, more preferably between 2 to 200 mg of the compounds of formula (I) l and the compounds (I. a), (l.b), (l.c), (l.d), (l.e), (l.f), (l.g) and (l.h).
- Each dosage unit may conveniently contain from 0,01 mg to 100 mg of the compounds of formula (I) 1, preferably from 0,1 to 50 mg.
- the dosage units are administered to the patient 1 , 2, 3, or 4 times daily. It is preferred that the dosage units are administered either three or fewer times, more preferably once or twice daily consecutively over a period of time.
- the dose is administered to a patient in the morning and the evening, more preferably once in the morning and once in the evening, most preferably once in the evening only consecutively over a period of time.
- Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate.
- the tablets may also comprise several layers. Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number or layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
- excipients for example inert
- Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g of. a flavouring such as vanilline or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
- a sweetener such as saccharine, cyclamate, glycerol or sugar
- a flavour enhancer e.g of. a flavouring such as vanilline or orange extract.
- suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
- Solutions for injection are prepared in the usual way, e.g of. with the addition of preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, and transferred into injection vials or ampoules.
- preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid
- Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
- Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
- the finely ground active substance, lactose and some of the corn starch are mixed together.
- the mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried.
- the granules, the remaining corn starch and the magnesium stearate are screened and mixed together.
- the mixture is compressed to produce tablets of suitable shape and size.
- the finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened.
- the sodium-carboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.
- the active substance, corn starch, lactose and polyvinylpyrrolidone are thoroughly mixed and moistened with water.
- the moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45°C and the granules are then passed through the same screen.
- convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine .
- the tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc.
- the finished coated tablets are polished with wax.
- the substance and corn starch are mixed and moistened with water.
- the moist mass is screened and dried.
- the dry granules are screened and mixed with magnesium stearate.
- the finished mixture is packed into size 1 hard gelatine capsules.
- the active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic.
- the solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion.
- the hard fat is melted.
- the ground active substance is homogeneously dispersed. It is cooled to 38°C and poured into slightly chilled suppository moulds.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne l'utilisation de dérivés de benzimidazolone représentés par la formule (I) en vue de la préparation d'un médicament destiné à traiter des maladies dans lesquelles l'utilisation de quantités thérapeutiquement efficaces de composés présentant une affinité pour le récepteur 5-HT2B présente un bénéfice thérapeutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06124577 | 2006-11-22 | ||
EP06124577.5 | 2006-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008061968A1 true WO2008061968A1 (fr) | 2008-05-29 |
Family
ID=39093062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/062537 WO2008061968A1 (fr) | 2006-11-22 | 2007-11-20 | Dérivés de benzimidazolone utiles dans le traitement de l'hypertension artérielle pulmonaire |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008061968A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2184276A1 (fr) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Procédé de préparation de nouvelles 1H-benzo(d) imidazol-2(3h)-ones substituées, de nouveaux intermédiaires et leur utilisation en tant qu'inhibiteurs de bace 1 |
CN103467596A (zh) * | 2012-06-06 | 2013-12-25 | 北京大学 | 一个治疗肺动脉高压的新靶点 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021593A1 (fr) * | 1999-09-22 | 2001-03-29 | Boehringer Ingelheim Italia S.P.A. | Nouveaux derives de benzimidazolone possedant une affinite mixte envers les recepteurs de serotonine et de dopamine |
US20050222176A1 (en) * | 2003-03-31 | 2005-10-06 | Dhanoa Dale S | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US20060120972A1 (en) * | 2004-11-09 | 2006-06-08 | Peter Engels | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension |
-
2007
- 2007-11-20 WO PCT/EP2007/062537 patent/WO2008061968A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021593A1 (fr) * | 1999-09-22 | 2001-03-29 | Boehringer Ingelheim Italia S.P.A. | Nouveaux derives de benzimidazolone possedant une affinite mixte envers les recepteurs de serotonine et de dopamine |
US20050222176A1 (en) * | 2003-03-31 | 2005-10-06 | Dhanoa Dale S | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US20060120972A1 (en) * | 2004-11-09 | 2006-06-08 | Peter Engels | 9-(N-methyl-piperidyliden-4)-thioxanthene for treatment of pulmonary hypertension |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2184276A1 (fr) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Procédé de préparation de nouvelles 1H-benzo(d) imidazol-2(3h)-ones substituées, de nouveaux intermédiaires et leur utilisation en tant qu'inhibiteurs de bace 1 |
US7906541B2 (en) | 2008-11-07 | 2011-03-15 | Universite Paul Cezanne-Aix Marseille Iii | Process to prepare new substituted 1H-benzo[d]imidazol-2(3H)-ones, new intermediates and their use as BACE 1 inhibitors |
CN103467596A (zh) * | 2012-06-06 | 2013-12-25 | 北京大学 | 一个治疗肺动脉高压的新靶点 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10098876B2 (en) | Treating sexual desire disorders with flibanserin | |
CA2626134C (fr) | Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme | |
EP1740180B1 (fr) | Utilisation de flibanserine dans le traitement des troubles premenstruels | |
EP1945215A2 (fr) | Medicaments augmentant le desir sexuel comprenant des derives de benzimidazolone | |
AU2002333894A1 (en) | Use of flibanserin in the treatment of sexual disorders | |
EP1768670A1 (fr) | Utilisation de flibanserine pour le traitement de l'anorexie mentale | |
EP1789048A1 (fr) | Methode de traitement du trouble de l'hyperactivite avec deficit de l'attention | |
WO2007128802A2 (fr) | Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques | |
WO2008061968A1 (fr) | Dérivés de benzimidazolone utiles dans le traitement de l'hypertension artérielle pulmonaire | |
WO2008061966A2 (fr) | Nouvelle utilisation de la flibansérine | |
US11058683B2 (en) | Treating sexual desire disorders with flibanserin | |
US20100022558A1 (en) | Treatment of insomnia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07822717 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07822717 Country of ref document: EP Kind code of ref document: A1 |